Cargando…

FDA remote evaluation of drug manufacturing during COVID-19

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062823/
http://dx.doi.org/10.1007/s40278-021-94456-0
_version_ 1783681842807832576
collection PubMed
description
format Online
Article
Text
id pubmed-8062823
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-80628232021-04-23 FDA remote evaluation of drug manufacturing during COVID-19 Reactions Weekly News Item Springer International Publishing 2021-04-24 2021 /pmc/articles/PMC8062823/ http://dx.doi.org/10.1007/s40278-021-94456-0 Text en © Springer International Publishing AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle News Item
FDA remote evaluation of drug manufacturing during COVID-19
title FDA remote evaluation of drug manufacturing during COVID-19
title_full FDA remote evaluation of drug manufacturing during COVID-19
title_fullStr FDA remote evaluation of drug manufacturing during COVID-19
title_full_unstemmed FDA remote evaluation of drug manufacturing during COVID-19
title_short FDA remote evaluation of drug manufacturing during COVID-19
title_sort fda remote evaluation of drug manufacturing during covid-19
topic News Item
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062823/
http://dx.doi.org/10.1007/s40278-021-94456-0